3. Umbruch 4.4..2005 - Online Pot

Cannabidiol as a potential medicine 51
Table 2. Some actions of CBD expected to affect neurotransmission
Action Tissue Effective concentration Reference
Antagonism of cannabinoid CB1 receptor agonists Mouse vas deferens 120 nM (KB value) [47]
Inhibition of Ca 2+ uptake Rat brainstem synaptosomes 100 nM [45]
Inhibition of Ca 2+ uptake Mouse brain synaptosomes 1 µM [45]
Inhibition of 5-HT uptake Rat hypothalamic synaptosomes 1 µM [41]
Inhibition of dopamine and noradrenaline uptake Rat striatal or hypothalamic 1 µM [41, 49]
synaptosomes
Displacement of [ 3 H]SR-141716A from CB1 receptors CB1-containing membranes 1.26 µM (Ki value) [51]
Displacement of 3 H-CP-55,940 from CB1 receptors CB1-containing membranes 2.28 µM (Ki value) [50, 51]
4.35 µM (Ki value)
Enhancement of evoked neuronal release of noradrenaline and ATP Mouse vas deferens 3.2 µM [47]
Inhibition of dopamine and noradrenaline uptake Mouse whole-brain synaptosomes 5 µM [46]
Inhibition of 5-HT and GABA uptake Mouse whole-brain synaptosomes 10 µM [46]
Enhancement of basal release of dopamine and noradrenaline Rat striatal and hypothalamic 10 µM [49]
synaptosomes
Antagonism of the cannabinoid CB1 receptor agonist CP-55,940 Rat cerebellar membranes 10 µM [48]
Inhibition of choline uptake Rat hippocampal crude synaptosomal 16 µM (EC50) [28]
fraction
Inhibition of anandamide uptake RBL-2H3 cells 22 µM (EC50) [42]
Inhibition of anandamide metabolism N18TG2 cell membranes 27.5 µM (EC50) [42]
Attenuation of the affinity of dopamine D2 receptor ligands for D2 Mouse striatal membranes 30 µM [43, 44]
receptors
GABA, γ-aminobutyric acid; 5-HT, 5-hydroxytryptamine.